Well it’s been a very long…long…long time since I wrote to you. I think I still wore flannel PJ’s back then…!!! Life’s been good for the most part and I tried to live an honest and moral life. So I hope that you will consider my wishes for this coming holiday season.
Please place beneath my Christmas tree the following.
12-10-15 PPHM C.C…Today PPHM announces that it’s wholly owned subsidiary AVID Bioservices has firm new contracts for it’s new AVID II facilities of over $50M and are now projecting revenue for fiscal year 2016 to exceed $45M…Or something like that.
Before 12-31-15 PPHM announces that its pivotal clinical trial SUNRISE has now completed enrollment and we look forward to updating you as the data matures…Along with some suitable words of enthusiasm and encouragement.
Before 12-31-15 PPHM announces the initiation of a new Phase II/III trial to evaluate bavituximab with chemotherapy combinations in HER2-negative metastatic breast cancer.
I thank you in advance for your consideration. And please remember…this request is not only for me but for the many cancer patients and families that are now suffering and of course…for the many loyal shareholders…Some of whom appear to be rapidly losing it.
Yours truly and humbly golfho
So now my fellow Ihub board members…I will simultaneously step into the murky waters of prognostication and fictional writing.
SO YOU ASK… WHAT ABOUT THIS:
“Peregrine announced plans to expand the bavituximab clinical development program to include a Phase II trial to evaluate the combination of bavituximab and Opdivo® (nivolumab), an anti-PD-1 antibody, in previously treated, metastatic NSCLC. This trial is expected to be initiated by the end of calendar year 2015.”
BMY: Hay Steve congratulation on completing enrollment on our Yervoy combo trial. I gotta tell ya…some of the boys on the board didn’t think you guys were capable…But I told them…What the hell…they’re paying for it anyways…But that’s not why I called…I called to finalize our pricing for the Opdivo that we will be supplying to you for our next combo trial. Some on the board thought that providing a 10% discount would be a nice thing but I said…Why…They are already conditioned to paying full retail…Why change thing?...Right…? STEVE: Oh…!!! Well…!!! I mean…!!! Geez…!!! Well here’s the thing…We have these peeps…You know them…K & L Gates…They’re telling me…Look PUTZ…You already have an agreement with AZ that will test their PD-L1 candidate for free why would you need to pay those smucks at BMY for their PD-1…??? Oh…! and by the way…they said that there are indications that the PD-L1 pathway might be better that PD-1…Just saying. BMY: YOU SNIVELING POS. HOW DARE YOU. Do you know who you are talking too? I’M MR. “A” I eat people like you for lunch…I’ll get more in a severance package that your entire puny company is worth right now…I will squash you like a cockroach… STEVE: Well…Umm…Oh…Sorry Sir…But…But…Here’s the thing…I paid them a lot of money and they advise me as to what I should do. You do understand…No…? And what they are telling me is…Why settle for less when you already have more…??? Kinda make sense to me…No…??? anyway…I’d love to chat more but I have other calls to answer…Calls from AstraZeneca, Roach and Merck…Let’s talk later about going forward…We’re thinking more along the lines of a 50-50 split on cost and revenue…Have a great day… BMY: WHY YOU UNGRATEFUL LITTLE PIECE OF SHI… STEVE: click...
Now on to the first immunotherapy combo for PPHM against melanoma. We have completed enrollment, in my view…on time. At this time the company should know how the data is trending. There are two major conferences in the first half of 2016. NYAS in late February and ASCO in June. If the data is impressive I would hope that it would be presented during one of those two.
The two clinical trials with AZ’s durvalumab should start in the first quarter of 2016:
“AstraZeneca's anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736), in a global Phase II study in patients with previously treated squamous or non-squamous non-small cell lung cancer (NSCLC)”
and
“Phase I/Ib basket clinical trial evaluating the combination of bavituximab and durvalumab with chemotherapy in multiple solid tumors.”
At this point I don’t think that either Roach or Merck can wait much longer. They may want a peek at the Yervoy data first…but time is now going against them.
Market Data 
Markets 
AI
